Prostate-specific antigen–based prostate cancer early detection efforts that aim to identify high-risk, potentially lethal cancers still in the window of opportunity for cure have helped decrease age-adjusted mortality rates by nearly half since the 1990s. Here, KLK3 is linked to prostate cancer.